Rodney A. Beck - Concepedia

Author

Rodney A. Beck

Clearview Cancer Institute

Also Known As

Rodney A Beck, Rodney A. Beck, Rodney Beck

Publications

477

Citations

H-Index

Concepts

All Affiliations

Clearview Cancer Institute University of Rochester ID Genomics (United States)

About

Rodney A. Beck is an author at Clearview Cancer Institute specializing in pathology, cancer research, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	129
2	Pathology	2	2	129
3	Immunology	1	1	91
4	Bioinformatics	1	1	38
5	Biomarker Discovery	1	1	38

Rodney A. Beck

Publications

469

Citations

H-Index

Page 1

	Year	Citations
Mammostrat®as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy John M.S. Bartlett, Jeremy Thomas, Douglas T. Ross, Breast Cancer Research	2010	118
A novel five-antibody immunohistochemical test for subclassification of lung carcinoma Brian Z. Ring, Robert S. Seitz, Rodney A. Beck, Modern Pathology Cancer DetectionLung CarcinomaMedicineMultiple Pulmonary NoduleImmunology	2009	91
Mammostrat As an Immunohistochemical Multigene Assay for Prediction of Early Relapse Risk in the Tamoxifen Versus Exemestane Adjuvant Multicenter Trial Pathology Study John M.S. Bartlett, Kenneth J. Bloom, Tammy Piper, Journal of Clinical Oncology	2012	65
Chemosensitivity and Stratification by a Five Monoclonal Antibody Immunohistochemistry Test in the NSABP B14 and B20 Trials Douglas T. Ross, Chung-yeul Kim, Gong Tang, Clinical Cancer Research	2008	65
The expression of TRMT2A, a novel cell cycle regulated protein, identifies a subset of breast cancer patients with HER2 over-expression that are at an increased risk of recurrence David G. Hicks, Bagi R. Janarthanan, Ramya Vardarajan, BMC Cancer	2010	38
A Search for Reliable Molecular Markers of Prognosis in Prostate Cancer Alison Tradonsky, Tammy Rubin, Rodney A. Beck, American Journal of Clinical Pathology PathologyBiopsy SpecimensReliable Molecular MarkersBiopsy TissueGenitourinary Cancer	2012	38
TLE3 as a candidate biomarker of response to taxane therapy Swati Kulkarni, David G. Hicks, Nancy Watroba, Breast Cancer Research	2009	27
Angiosarcoma: a study of 98 cases with immunohistochemical evaluation of TLE3, a recently described marker of potential taxane responsiveness Wonwoo Shon, Sarah M. Jenkins, Douglas T. Ross, Journal of Cutaneous Pathology	2011	27

Page 1